---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-24-000085"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:36:28.764179+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Spyre Therapeutics reports Q3 net loss of $69M; pipeline on track with SPY001 Phase 1 data by year-end

## Summary
- Net loss of $69.0M in Q3 2024 (vs $40.1M in Q3 2023); R&D expenses rose to $44.7M from $24.7M.
- Cash, cash equivalents and marketable securities of $414.2M as of Sep 30, 2024; runway extended well into 2027.
- SPY001 Phase 1 interim data expected by year-end 2024; SPY002 FIH trials initiated in Q4 2024.
- Appointed Sheldon Sloan, M.D., as Chief Medical Officer, effective October 2024.
- Preclinical data for SPY003 at UEGW showed >3-fold half-life extension vs risankizumab; FIH accelerated to Q1 2025.

## SEC filing metadata
- accession: 0001636282-24-000085
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000085/0001636282-24-000085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000085/syre-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-24-000085
- JSON: https://secwatch.observer/filing/0001636282-24-000085.json
- Plain text: https://secwatch.observer/filing/0001636282-24-000085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.